What we do
APIs and Intermediates:
We are a specialized pharma company focusing on niche therapeutic areas of CNS,
ARVs and controlled substances. Our specialization in unique CNS segments like ADHD,
Anti-psychotics, Anti-vertigo, Anti-inflammatory, Pain management, Alzheimer disease
and others gives ZCL the leverage to outclass the competition. We are moving up
the value chain adding capacity for more APIs.
CMO:
With the best in class manufacturing facilities with accreditation and state-of-the-art
research platform besides brilliant minds in our R&D we have embarked on establishing
contract manufacturing organization. We have many on-going contract manufacturing
projects that involve complex chemistry and technological excellence.
Active Pharma Ingredients (APIs)
|
Product
|
Status
|
Pharmacoepeia
|
CAS No.
|
Therapeutic Use
|
Enquiry
|
|
Alprazolam
|
Tech pack
|
USP/EP
|
28981-97-7
|
Anxiolytic
|
|
|
Aripiprazole
|
USDMF⁺, CEP & WC
|
USP/EP
|
129722-12-9
|
Anti-depressant/Anti-psychotic
|
|
|
Atomoxetine HCl
|
CEP, USDMF⁺, TDMF, IDL⁺ & WC
|
USP/EP
|
82248-59-7
|
Attention Deficit Hyperactivity Disorder (ADHD)
|
|
|
Betahistine Dihydrochloride
|
CEP, TDMF & WC
|
USP/BP/EP/IP
|
5579-84-0
|
Vertigo
|
|
|
Betahistine Mesylate
|
Tech pack
|
EP/JP/IP
|
54856-23-4
|
Vertigo
|
|
|
Clozapine
|
USDMF⁺, CEP* & WC*
|
USP/EP/IP
|
5786-21-0
|
Anti-psychotic
|
|
|
Dexmethylphenidate HCl
|
Tech pack
|
Inhouse
|
19262-68-1
|
Attention Deficit Hyperactivity Disorder (ADHD)
|
|
|
Eslicarbazepine Acetate
|
Tech pack
|
In-house/IP
|
236395-14-5
|
Anti-epileptic
|
|
|
Felbinac
|
EDMF*, JDMF* & WC
|
BP/EP/JP
|
5728-52-9
|
Anti-inflammatory
|
|
|
Fluvoxamine Maleate
|
CEP, USDMF⁺, TDMF & WC
|
USP/BP/EP/IP
|
61718-82-9
|
Anti-depressant
|
|
|
Levomepromazine Maleate
|
CEP* & WC
|
EP/JP
|
7104-38-3
|
Anti-psychotic
|
|
|
Loxoprofen sodium
|
Tech pack
|
JP
|
80382-23-6
|
Anti-inflammatory, Analgesic
|
|
|
Lurasidone HCl
|
USDMF⁺
|
In-house
|
367514-88-3
|
Anti-psychotic
|
|
|
Memantine HCl
|
USDMF⁺, AUSDMF* & WC
|
USP
|
41100-52-1
|
Alzheimer Disease
|
|
|
Methylphenidate HCl
|
CEP⁺
|
USP/EP
|
298-59-9
|
Attention Deficit Hyperactivity Disorder (ADHD)
|
|
|
Mirabegron
|
Tech pack
|
In-house
|
223673-61-8
|
Treatment of overactive bladder
|
|
|
Modafinil
|
Tech pack
|
USP/EP
|
68693-11-8
|
CNS Stimulant
|
|
|
Olanzapine
|
Tech pack
|
USP
|
132539-06-1
|
Anti-psychotic
|
|
|
Phenylephrine hydrochloride
|
Tech pack
|
EP/IP
|
61-76-7
|
Decongestant
|
|
|
Pirfenidone
|
USDMF* & CEP*
|
In-house
|
53179-13-8
|
Anti-Inflammatory / Anti-Rheumatic
|
|
|
Pregabalin
|
Tech pack
|
In-house
|
148553-50-8
|
Epilepsy, Neuropathic pain and generalized anxiety disorder
|
|
|
Quetiapine Fumarate
|
USDMF⁺, AUSDMF* & CEP⁺
|
USP/EP
|
111974-72-2
|
Anti-psychotic
|
|
|
Rivaroxaban
|
USDMF⁺
|
In-house
|
366789-02-8
|
Anti-coagulant
|
|
|
Trifluoperazine HCl
|
Tech pack
|
USP/BP/EP/IP
|
440-17-5
|
Anti-psychotic
|
|
|
Zaltoprofen
|
KDMF
|
JP
|
74711-43-6
|
Anti-inflammatory
|
|
|
Zonisamide
|
Tech pack & WC*
|
USP
|
68291-97-4
|
Anti-convulsant
|
|
|
|
|
Product Pipeline
|
|
Dapagliflozin propanediol monohydrate
|
Under development
|
In-house
|
960404-48-2
|
Anti-diabetic
|
|
|
Darunavir ethanolate
|
Under development
|
In-house
|
635728-49-3
|
Treatment of AIDS and HIV infections
|
|
|
Empagliflozin
|
Under development
|
In-house
|
864070-44-0
|
Anti-diabetic
|
|
|
|
|
Product under evaluation
|
|
Betrixaban
|
Under evaluation
|
In-house
|
330942-05-7
|
Anticoagulant
|
|
|
Brivaracetam
|
Under evaluation
|
In-house
|
357336-20-0
|
Anti-Epileptics;Analgesics
|
|
|
Edaravone
|
Under evaluation
|
In-house
|
89-25-8
|
Neurology(Orphan drug)
|
|
|
Ertugliflozin
|
Under evaluation
|
In-house
|
1210344-57-2
|
Anti-diabetic
|
|
|
Pimavanserin
|
Under evaluation
|
In-house
|
706779-91-1
|
Antipsychotic
|
|
|
Safinamide Mesylate
|
Under evaluation
|
In-house
|
133865-89-1
|
Anti-Epileptics;Anti-Parkinson Drugs
|
|
|
Valbenazine tosylate
|
Under evaluation
|
In-house
|
1639208-54-0
|
Tardive dyskinesia
|
|
*Under filing, + Applied, WC = Written confirmation
Disclaimer:
Users are responsible for all patent related issue for our offered products.
The therapeutic use shown against each product is indicative only and is not for
advertising ZCL products.
Patented Products are available for R&D use as per permitted under 35 USC 271 (e)
(1)
Advanced Intermediates
|
Product
|
CAS No.
|
End Use
|
Structure
|
Enquiry
|
|
(1H)-7-(4’-bromobutoxy)-3,4-dihydro-2-quinolinone
|
1297225-34-5
|
Aripiprazole
|
|
|
|
1-(2,3-Dichlorophenyl) Piperazine HCl
|
119532-26-2
|
Aripiprazole
|
|
|
|
3-(methylamino)-1-phenylpropan-1-ol
|
42142-52-9
|
Atomoxetine Fluoxetine Nisoxetine
|
|
|
|
N-Benzhydrylpiperazine
|
841-77-0
|
Cinnarizine
|
|
|
|
Benzenesulfonamide, 4-amino-N-[(2R,3S)-3-amino-2- hydroxy-4-phenylbutyl]-N-(2-methylpropyl)
|
169280-56-2
|
Darunavir
|
|
|
|
Carbamic acid, N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-nitrophenyl)sulfonyl]amino]-1-
(phenylmethyl)propyl]-,1,1-dimethylethylester
|
191226-98-9
|
Darunavir, Fosamprenavir
|
|
|
|
N-(1,4-Benzodioxan-2-carbonyl)-piperazine
|
70918-00-2
|
Doxazosin
|
|
|
|
(10S)-10,11-Dihydro-10-hydroxy-5Hdibenz[b,f]azepine-5-carboxamide
|
104746-04-5
|
Eslicarbazepine acetate
|
|
|
|
10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide
|
29331-92-8
|
Eslicarbazepine acetate
|
|
|
|
4-Hydroxy-3, 5-dimethyl benzonitrile
|
4198-90-7
|
Etravirine
|
|
|
|
4,4'-Difluorobenzhydrylpiperazine
|
27469-60-9
|
Flunarizine
|
|
|
|
(1E)-N-Hydroxy-5-Methoxy-1-(4-Trifluoromethylphenyl)Pentan-1-Imine
|
61747-22-6
|
Fluvoxamine
|
|
|
|
2-Bromo-4'-benzyloxy-3'-nitroacetophenone
|
43229-01-2
|
Formoterol
|
|
|
|
2,4-Dihydro-4-[4-[4-(4-methoxyphenyl)-1- piperazinyl]phenyl]-2-(1-methyl propyl)-3H-1,2,4-triazol-3-one
|
252964-68-4
|
Itraconazole
|
|
|
|
1-Acetyl-4-(4-hydroxyphenyl) piperazine
|
67914-60-7
|
Ketoconazole
|
|
|
|
2-{4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid
|
68767-14-6
|
Loxoprofen Sodium
|
|
|
|
1R)-2-{[2-(4-aminophenyl)ethyl]amino}-1-phenylethanol hydrochloride
|
521284-22-0
|
Mirabegron
|
|
|
|
(1R)-2-{[2-(4-nitrophenyl)ethyl]amino}-1-phenylethanol
|
223673-34-5
|
Mirabegron
|
|
|
|
2-Methyl-10H-thieno[2,3-b][1,5] benzo diazepine-4-amine HCl
|
138564-60-0
|
Olanzapine
|
|
|
|
5-methyl-2-(2-nitrophenylamino) thiophene-3-carbonitrile
|
138564-59-7
|
Olanzapine
|
|
|
|
(R)-(-)-3-Carbamoylmethyl-5-methylhexanoic acid
|
181289-33-8
|
Pregabalin
|
|
|
|
5-methylpyridin-2(1H)-one (synonym : 2-Hydroxy-5-methylpyridine)
|
1003- 68-5
|
Pirfenidone
|
|
|
|
1-Aminoindan
|
34698-41-4
|
Rasagiline
|
|
|
|
4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one hydrochloride
|
898543-06-1
|
Rivaroxaban
|
|
|
|
2-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl]-1,3-oxazolidin-5-yl}methyl)-1H-isoindole-1,3(2H)-dione
|
446292-08-6
|
Rivaroxaban
|
|
|
|
N-Isopropyl-4-(4-hydroxyphenyl)-piperazine
|
67914-97-0
|
Terconazole
|
|
|
|
2-(Trifluoromethyl)-phenothiazine
|
92-30-8
|
Trifluoperazine
|
|
|
Disclaimer:
Users are responsible for all patent related issue for our offered products.
The therapeutic use shown against each product is indicative only and is not for
advertising ZCL products.
Patented Products are available for R&D use as per permitted under 35 USC 271 (e)
(1)
Under Scale-up / New Development
|
Product
|
CAS No.
|
End Use
|
Status
|
Structure
|
Enquiry
|
|
1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-,2,3,4,6-tetraacetate,
(1S)- D-Glucitol
|
461432-25-7
|
Dapagliflozin propanediol
|
Under development
|
|
|
|
(2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol
|
714269-57-5
|
Dapagliflozinpropanediol
|
Under development
|
|
|
|
1-Choro-4-(B-D-glucopyranos-1yl)-2-(4-hydroxy-benzyl)-benzene
|
864070-37-1
|
Empagliflozin
|
Under development
|
|
|
|
4-(5-bromo-2-chlorobenzyl) phenol(synonym : [(5-bromo-2-chlorobenzyl)-methyl] phenol
|
864070-18-8
|
Empagliflozin
|
Under development
|
|
|
|
(4-(5-bromo-2-chlorobenzyl)phenoxy)(tertbutyl)dimethylsilane
|
864070-19-9
|
Empagliflozin
|
Under development
|
|
|
|
(2S,3S,4R,5R,6R)-2-(3-(4-acetoxybenzyl)-4-chlorophenyl)-6-(acetoxymethyl)tetrahydro-2Hpyran-3,4,5-triyltriacetate
|
912917-85-2
|
Empagliflozin
|
Under development
|
|
|
|
(R)-tetrahydrofuran-3-yl 4-methylbenzene sulfonate
|
219823-47-9
|
Empagliflozin
|
Under development
|
|
|
|
4-Amino-2-fluoro-N-methylbenzamide
|
915087-25-1
|
Enzalutamide
|
Underscale-up
|
|
|
|
N-Methyl-2-fluoro-4-(1,1-dimethyl cyanomethyl) aminobenzamide
|
915087-32-0
|
Enzalutamide
|
Under scaleup
|
|
|
Disclaimer:
Users are responsible for all patent related issue for our offered products.
The therapeutic use shown against each product is indicative only and is not for
advertising ZCL products.
Patented Products are available for R&D use as per permitted under 35 USC 271 (e)
(1)
Disclaimer
Information given herein is offered in good faith as accurate, but without guarantee.
Conditions of use and suitability of the product for particular uses are beyond
our control. All risks of use of the product are therefore assumed by the user.
ZCL Chemicals Limited EXPRESSLY DISCLAIMS ALL WARRANTIES OF EVERY KIND AND NATURE,
INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE IN
RESPECT TO THE USE OR SUITABILITY OF THE PRODUCT. Appropriate warnings and safe
handling procedures should be provided to handlers and users.
Alteration of this document is strictly prohibited.
No statement contained herein concerning a possible or suggested use of any material,
product or design is intended, or should be construed, to grant any license under
any patent or other intellectual property right of ZCL Chemicals Limited or any
of its associates or its affiliates covering such use or design, or as a recommendation
for the use of such material, product or design in the infringement of any patent
or other intellectual property right. The products are sold subject to ZCL Chemicals
Limited Standard Conditions of Sale, which are available upon request.